Joel M. Gelfand, MD, MSCE
Professor of Dermatology and Epidemiology,
Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
This enduring activity is designed to meet the educational needs of US-based rheumatologists, dermatologists and other allied healthcare professionals involved in the management of patients with psoriatic diseases.
This activity is intended for rheumatologists, dermatologists, and other healthcare professionals involved in the management of patients with psoriasis and psoriatic arthritis.
Upon completion of this activity, participants will be able to:
- Review recent advances in the understanding of psoriatic disease pathophysiology
- Explain the link between psoriatic diseases and cardiovascular disease and the rationale and evidence for screening and management of cardiovascular disease in patients with psoriatic diseases
- Describe the mechanisms of action of new and emerging biologics for psoriatic diseases and critically evaluate their efficacy/safety profile in patients with moderate to severe psoriasis and active psoriatic arthritis
- Discuss the impact of approved and investigational biologics on kinetics of responses, skin clearance, patients’ symptoms, and quality of life, and how to individualize the management of psoriatic diseases based on these factors
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care for patients with psoriasis and psoriatic arthritis.
Credits: 1.25 ANCC Contact Hour(s)
CNE Accreditation Statement: Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
In the previous 12 months, Dr. Gelfand has served as a consultant for and received honoraria from AbbVie, Astrazeneca, Celgene Corp, Coherus, Lilly, Janssen Biologics (formerly Centocor), Sanofi, Merck, Novartis Corp,, Valeant, and Pfizer Inc.; he receives research grants (to Trustees of the University of Pennsylvania) from AbbVie, Lilly, Janssen, Sanofi, Novartis Corp, Regeneron, and Pfizer Inc.; and he received payment for continuing medical education work related to psoriasis. Dr. Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Chris Drury, MA, MS, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Matthew Frese, MBA, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Ana Goffin, MPA, Program Manager for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, Dr. Gelfand may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Internet Explorer (v6 or greater), or Firefox
RELEASE DATE: May 8, 2017
EXPIRATION DATE: May 8, 2018
COURSE TOPIC: Psoriasis and Psoriatic Arthritis
Estimated Time to Complete This Educational Activity: 75 minutes
This educational activity provides training necessary for licensed attendees to maintain state licensing requirements. The tuition for this educational activity is subsidized in part by unrestricted educational grants, including for those attendees who have successfully completed the state licensing requirements for their respective fields. This subsidy is reflected in the registration fees for this activity.
Copyright © 2017 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.